Genmab (GMAB) has released an update.
Genmab A/S, a leading biotechnology firm, is making strides in its share buy-back program, aiming to repurchase shares worth up to DKK 3.5 billion by December 16, 2024. Recent transactions under this program have successfully accumulated a total value of DKK 504,835,345.59. This buy-back aligns with the company’s strategy to enhance shareholder value and is conducted in compliance with the EU’s Market Abuse Regulation and Safe Harbour rules.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
